No Data
No Data
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Supernus Pharmaceuticals Down Over 8%, On Track for Largest Percent Decrease Since February 2021 -- Data Talk
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Supernus Cut to Neutral at Piper Sandler on Qelbree Growth Trajectory
Arrayfunction : Do you have any experience with Phase 4 / aftermarket trials for medical devices or durable medical equipment? That's something I would like to educate myself on but I honestly have a much harder time with devices. For one, my company doesn't really do those anymore. But mainly it's the extra categories (e.g. FDA authorized de novo and approval on the basis of similarities to an established device) that I struggle with.
I'd appreciate the help! But no worries if not
Jaguar8 OP Arrayfunction : No. I do not come from any clinical research companies and/or pharma which does Ph 4.
Arrayfunction Jaguar8 OP : Thanks!